CIK 0001231457 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
GENELUX Corp
Sign in to watch- Ticker
- GNLX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 805-267-9889
- Business address
- 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE, CA, 91361
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $155,693
- in 6 filings
Net −$155,693. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 71 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-16 | Yu Yong Chief Scientific Officer | Grant or award | +119,318 | 269,024 | ||
| 2026-06-16 | Smither John W Director | Grant or award | +28,409 | 103,403 | ||
| 2026-06-16 | Smither John W Director | Grant or award · Stock Option (Right to Buy) | +31,566 | 31,566 | ||
| 2026-06-03 | Smalling Ralph Head of Regulatory | Sale | −192 | $2.93 | $563 | 67,611 |
| 2026-06-01 | Thomas John Director | Sale 10b5-1 | −10,000 | $2.98 | $30K | 472,784 |
| 2026-05-11 | Cappello Joseph Chief Technical Officer | Sale | −605 | $2.97 | $2K | 154,549 |
| 2026-05-11 | Yu Yong Chief Scientific Officer | Sale | −605 | $2.97 | $2K | 149,706 |
| 2026-05-11 | Zindrick Thomas President and CEO | Sale | −2,798 | $2.94 | $8K | 532,051 |
| 2026-05-11 | Smalling Ralph Head of Regulatory | Sale | −270 | $2.98 | $804 | 67,803 |
| 2026-03-25 | Smalling Ralph Head of Regulatory | Sale | −240 | $2.51 | $602 | 68,073 |
| 2026-03-24 | Smalling Ralph Head of Regulatory | Sale | −345 | $2.42 | $835 | 68,313 |
| 2026-03-24 | Cappello Joseph Chief Technical Officer | Sale | −906 | $2.42 | $2K | 155,154 |
| 2026-03-24 | Yu Yong SVP, Clinical Development | Sale | −906 | $2.42 | $2K | 144,938 |
| 2026-03-24 | Zindrick Thomas President and CEO | Sale | −3,582 | $2.42 | $9K | 534,849 |
| 2026-03-02 | Thomas John Director | Sale 10b5-1 | −10,000 | $2.90 | $29K | 482,784 |
| 2026-01-02 | Litten Jason Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +275,000 | 275,000 | ||
| 2025-12-05 | Smalling Ralph Head of Regulatory | Sale | −165 | $4.69 | $774 | 68,658 |
| 2025-12-01 | Thomas John Director | Sale 10b5-1 | −10,000 | $5.00 | $50K | 492,784 |
| 2025-11-17 | Zindrick Thomas President and CEO | Sale | −4,509 | $5.37 | $24K | 538,431 |
| 2025-11-17 | Yu Yong SVP, Clinical Development | Sale | −973 | $5.37 | $5K | 145,844 |
Page 2 of 9 · 170 trades